CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a a Simon's two-stage, non-randomized, open label, 2-arm Phase II trial of ONC201 in women with metastatic or recurrent Type II endometrial...
Phase 2
Philadelphia, Pennsylvania, United States of America and 2 other locations
letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until eit...
Phase 2
Willow Grove, Pennsylvania, United States and 28 other locations
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with plati...
Phase 3
Philadelphia, Pennsylvania, United States and 187 other locations
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...
Phase 1
Philadelphia, Pennsylvania, United States and 20 other locations
(paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial...
Phase 3
Camden, New Jersey, United States and 202 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
Philadelphia, Pennsylvania, United States and 162 other locations
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer...
Phase 2
Philadelphia, Pennsylvania, United States and 1 other location
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in...
Phase 2
Philadelphia, Pennsylvania, United States and 16 other locations
in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-re ...
Phase 1
Philadelphia, Pennsylvania, United States and 17 other locations
who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, e....
Phase 1
Philadelphia, Pennsylvania, United States and 21 other locations
Clinical trials
Research sites
Resources
Legal